FDA LETTER LIBRARY

Complete response & enforcement letters

Name: FDA Complete Response & Enforcement Letters
Creator: Assyro AI
License: https://www.usa.gov/government-works

One place to review FDA responses, identify remediation themes, and open the interactive co-pilot for every letter.

Showing 253-264 of 291 letters

ALApproval Letter
Approval Letter Other 761115 (Jan 1, 2020)
This is a Complete Response Letter (CRL) from the FDA regarding Biologics License Application (BLA) 761115 for sacituzumab govitecan, indicating that the application cannot be approved in its present form due to various deficiencies related to product quality, manufacturing, labeling, facility inspections, and safety data.
IssuedJan 1, 2020
US FDA• sacituzumab govitecan powder for solution for infusion, intravenous, 180 mg
ALApproval Letter
Approval Letter Other 200655 (Jan 1, 2019)
The FDA issued a Complete Response letter for NDA 200655 for Fluorodopa F 18 Injection, indicating that the application cannot be approved in its current form due to significant deficiencies in clinical/statistical data, particularly regarding Study #17's design, conduct, and follow-up, which failed to provide sufficient confirmatory evidence of effectiveness. The letter also outlines requirements for labeling, safety updates, and the resubmission process.
IssuedJan 1, 2019
US FDA• Fluorodopa F 18 Injection, 0.42 mCi/mL to 8.33 mCi/ml
ALApproval Letter
Approval Letter Other 202408 (Jan 1, 2019)
This document contains multiple letters from the FDA to Fera Pharmaceuticals, LLC regarding New Drug Application (NDA) 202408 for Avaclyr (acyclovir ophthalmic ointment) 3%. It includes two 'Complete Response' letters detailing deficiencies preventing approval and required actions, and one 'Rescind Complete Response' letter indicating that a previous complete response was issued in error and the application is now under review.
IssuedJan 1, 2019
US FDA• Avaclyr (acyclovir ophthalmic ointment) 3%
ALApproval Letter
Approval Letter Other 202860 (Jan 1, 2019)
This is a Complete Response letter from the FDA to Vero Biotech, LLC, for their New Drug Application (NDA) 202860 for GeNOsyl® Delivery System (Nitric Oxide). The FDA has determined that the application cannot be approved in its present form due to deficiencies identified during facility inspections, issues related to the device's design and testing (CDRH concerns), and inadequacies in the human factors validation study.
IssuedJan 1, 2019
US FDA• GeNOsyl® Delivery System (Nitric Oxide)
ALApproval Letter
Approval Letter Other 206089 (Jan 1, 2019)
The FDA issued a Complete Response letter for Clarus Therapeutics, Inc.'s New Drug Application (NDA) for testosterone undecanoate (TU) (oral), indicating that the application cannot be approved in its present form due to several deficiencies related to safety, analytical methods, and nonclinical studies.
IssuedJan 1, 2019
US FDA• Jatenzo (testosterone undecanoate) (oral)
ALApproval Letter
Approval Letter Other 206927 (Jan 1, 2019)
This is a Complete Response letter from the FDA to Dr. Reddy's Laboratories, Limited, for New Drug Application (NDA) 206927/Original 1 for bortezomib for injection 3.5 mg/vial. The FDA has determined that the application cannot be approved in its present form and outlines specific deficiencies related to product quality, labeling, facility inspections, and safety updates, along with recommendations for addressing these issues.
IssuedJan 1, 2019
US FDA• bortezomib for injection 3.5 mg/vial
ALApproval Letter
Approval Letter Other 208193 (Jan 1, 2019)
The FDA issued a Complete Response Letter for New Drug Application (NDA) 208193 for Ozobax (baclofen) oral solution, indicating that the application cannot be approved in its current form. The letter outlines deficiencies related to product quality, including the need for additional stability studies and addressing gaps in the control strategy. It also details requirements for updating prescribing information and container labels to conform with regulatory standards, including using the SRPI checklist and submitting content in Structured Product Labeling (SPL) format. Furthermore, the applicant is required to submit a revised Initial Pediatric Study Plan (iPSP) and resubmit the proposed proprietary name. The letter provides recommendations for addressing these issues and specifies the process for resubmission or requesting a meeting.
IssuedJan 1, 2019
US FDA• Ozobax (baclofen) oral solution 1mg/mL
ALApproval Letter
Approval Letter Other 209354 (Jan 1, 2019)
The FDA issued a Complete Response Letter for NDA 209354, informing Dow Pharmaceutical Sciences, Inc. that their New Drug Application for halobetasol propionate and tazarotene lotion, 0.01%/0.045%, cannot be approved in its current form. The primary reason cited is insufficient nonclinical toxicology data, specifically a lack of an adequate bridge to listed drugs, and higher relative bioavailability of the proposed combination product. The letter outlines specific deficiencies and provides recommendations for resolution, including additional nonclinical studies and a comprehensive safety update.
IssuedJan 1, 2019
US FDA• halobetasol propionate and tazarotene lotion, 0.01%/0.045%
ALApproval Letter
Approval Letter Other 209863 (Jan 1, 2019)
The FDA issued a Complete Response letter for Antares Pharma, Inc.'s New Drug Application (NDA) 209863 for testosterone enanthate subcutaneous injection, indicating that the application cannot be approved in its current form due to identified deficiencies related to clinical safety, labeling, and other administrative aspects.
IssuedJan 1, 2019
US FDA• testosterone enanthate subcutaneous injection
ALApproval Letter
Approval Letter Other 210063 (Jan 1, 2019)
This document is a Complete Response letter from the FDA to Teva Pharmaceuticals USA, Inc. regarding their New Drug Application (NDA) 210063 for Fulvestrant Injection, 250 mg/5 mL. The FDA has determined that the application cannot be approved in its present form due to various deficiencies in nonclinical data, product quality, combination product (device) requirements, and labeling.
IssuedJan 1, 2019
US FDA• Fulvestrant Injection, 250 mg/5 mL
ALApproval Letter
Approval Letter Other 210649 (Jan 1, 2019)
This document is a Complete Response letter from the FDA to AB Pharmaceuticals, LLC, regarding New Drug Application (NDA) 210649 for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets. The FDA has determined that the application cannot be tentatively approved in its present form due to deficiencies related to facility inspections and prescribing information.
IssuedJan 1, 2019
US FDA• Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg
ALApproval Letter
Approval Letter Other 210895 (Jan 1, 2019)
This is a Complete Response letter from the FDA to Daiichi Sankyo Inc. regarding New Drug Application (NDA) 210895 for Welchol (colesevelam) chewable bar. The FDA has determined that the application cannot be approved in its present form due to product quality deficiencies related to manufacturing, and reserves comment on proposed labeling. The letter outlines specific actions required for resubmission.
IssuedJan 1, 2019
US FDA• Welchol (colesevelam) chewable bar, 3.75 grams

Page 22 of 25

1…20 21 22 23 24 25

Approval Letter Other 761115 (Jan 1, 2020)

Approval Letter Other 200655 (Jan 1, 2019)

Approval Letter Other 202408 (Jan 1, 2019)

Approval Letter Other 202860 (Jan 1, 2019)

Approval Letter Other 206089 (Jan 1, 2019)

Approval Letter Other 206927 (Jan 1, 2019)

Approval Letter Other 208193 (Jan 1, 2019)

Approval Letter Other 209354 (Jan 1, 2019)

Approval Letter Other 209863 (Jan 1, 2019)

Approval Letter Other 210063 (Jan 1, 2019)

Approval Letter Other 210649 (Jan 1, 2019)

Approval Letter Other 210895 (Jan 1, 2019)